| Titre |
Randomized Trial of Hypofractionated LocoRegional Radiotherapy in Breast Cancer and Lymphedema |
| Protocole ID |
RHEAL |
| ClinicalTrials.gov ID |
NCT04228991 |
| Type(s) de cancer |
Sein |
| Phase |
Phase III |
| Type étude |
Clinique |
| Institution |
CHU DE QUEBEC – UNIVERSITE LAVAL
 L'HOTEL-DIEU DE QUEBEC ET CRCEO
11 Côte du Palais, Québec, QC, G1R 2J6
|
| Ville |
Québec |
| Investigateur(trice) principal(e) |
Dre Valérie Théberge
|
| Coordonnateur(trice) |
Josée Allard
418-525-4444 poste 16730
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Newly diagnosed invasive carcinoma of the breast.
-
Treated with definitive surgery (BCS or mastectomy with nodal staging using SLNB or ALND) with clear margins of excision.*
Note: *Patients with limited positive posterior margin where disease is resected to chest wall or limited positive anterior margin where disease is resected to dermis are eligible.
-
Breast cancer stage after definitive surgery.
- if neoadjuvant chemotherapy was not administered: pathologic stage T1-3, N1-2
- if neoadjuvant chemotherapy was administered: clinical stage T1-3, N1-2 (histologically node positive) and pathologic stage T0-3, N0-2†
Note: †Patients who are histologically node positive prior to chemotherapy and who have complete response in the lymph nodes are eligible.
- No evidence of metastatic disease.
- Candidate for locoregional radiotherapy.
|
| Critètes d'exclusion |
- Age < 18 years.
- Clinical stages T4 and/or N3.
- Clinical lymphedema in the ipsilateral arm or breast/chest wall.
- Synchronous or previous contralateral breast cancer.
- Breast reconstruction.
- History of non-breast malignancy within the last 5 years other than non-melanoma skin cancer or treated in-situ carcinoma.
- Previous radiotherapy to the ipsilateral breast or chest wall or serious non-malignant disease e.g. scleroderma, severe lung or heart disease that would preclude radiotherapy.
- Known pregnancy or currently lactating.
- Geographic inaccessibility for follow-up.
- Inability to provide informed consent.
|
Groupe d'étude en oncologie du Québec